Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1982 1
1984 1
1988 1
1989 1
1992 1
1993 1
1994 2
1995 2
1997 3
1998 4
1999 2
2000 2
2001 2
2002 1
2003 2
2004 1
2005 1
2006 1
2007 1
2008 4
2009 4
2010 6
2011 2
2014 1
2015 4
2016 1
2017 1
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. McMurray JJV, et al. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. N Engl J Med. 2019. PMID: 31535829 Clinical Trial.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development.
Li J, Srivastava T, Rawal R, Manuel E, Isbell D, Tsark W, La Rosa C, Wang Z, Li Z, Barry PA, Hagen KD, Longmate J, Diamond DJ. Li J, et al. Virology. 2009 Apr 25;387(1):16-28. doi: 10.1016/j.virol.2009.01.041. Epub 2009 Feb 27. Virology. 2009. PMID: 19249807 Free PMC article.
Towards that goal, transgenic (Tg) mice expressing chimeric RM (alpha1 and alpha2 Mamu-A01 domains) and murine (alpha3, transmembrane, and cytoplasmic H-2K(b) domains) MHC Class I molecules were derived by transgenesis of the H-2K(b)D(b) double MHC Class I knockout strain. After …
Towards that goal, transgenic (Tg) mice expressing chimeric RM (alpha1 and alpha2 Mamu-A01 domains) and murine (alpha3, transmembrane, and c …
Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease.
Geethanjali FS, Luthra K, Lingenhel A, Kanagasaba-Pathy AS, Jacob J, Srivastava LM, Vasisht S, Kraft HG, Utermann G. Geethanjali FS, et al. Atherosclerosis. 2003 Jul;169(1):121-30. doi: 10.1016/s0021-9150(03)00143-6. Atherosclerosis. 2003. PMID: 12860258
Contrary to what has recently been observed in Black and White men short (K-IV<or=22) alleles associated with high Lp(a) concentration were not overrepresented in the patients. Rather, short (K-IV<or=22), intermediate (K-IV 23-29) and long (K-IV& …
Contrary to what has recently been observed in Black and White men short (K-IV<or=22) alleles associated with high Lp(a) concentra …
Glutathione S-transferases of female A/J mouse lung and their induction by anticarcinogenic organosulfides from garlic.
Hu X, Singh SV. Hu X, et al. Arch Biochem Biophys. 1997 Apr 15;340(2):279-86. doi: 10.1006/abbi.1997.9915. Arch Biochem Biophys. 1997. PMID: 9143332
Noticeably, an alpha class heterodimeric isoenzyme (pI 9.5) present in the forestomach of A/J mouse, which is exceptionally efficient in the glutathione (GSH) conjugation of (+)-anti-BPDE [X. Hu, S.K. Srivastava, H. Xia, Y. C. Awasthi, and S. V. Singh (1996) J. ...
Noticeably, an alpha class heterodimeric isoenzyme (pI 9.5) present in the forestomach of A/J mouse, which is exceptionally efficient in the …
Molecular basis of the medium-chain fatty acyl-CoA dehydrogenase-catalyzed "oxidase" reaction: pH-dependent distribution of intermediary enzyme species during catalysis.
Johnson JK, Kumar NR, Srivastava DK. Johnson JK, et al. Biochemistry. 1994 Apr 19;33(15):4738-44. doi: 10.1021/bi00181a033. Biochemistry. 1994. PMID: 8161532
In a previous paper, we demonstrated that the medium-chain fatty acyl-CoA dehydrogenase-catalyzed (MCAD-catalyzed) reductive half-reaction of indolepropionyl-CoA proceeds via formation of a chromophoric intermediary species "X" (absorption maximum = 400 nm) and proposed that the …
In a previous paper, we demonstrated that the medium-chain fatty acyl-CoA dehydrogenase-catalyzed (MCAD-catalyzed) reductive half-reaction o …
Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels.
Hanley PJ, Gopalan KV, Lareau RA, Srivastava DK, von Meltzer M, Daut J. Hanley PJ, et al. J Physiol. 2003 Mar 1;547(Pt 2):387-93. doi: 10.1113/jphysiol.2002.037044. Epub 2003 Jan 31. J Physiol. 2003. PMID: 12562916 Free PMC article.
Since 5-HD is thought to inhibit specifically the putative mitochondrial ATP-sensitive K+ (KATP) channel, this channel has been inferred to be a mediator of preconditioning. ...
Since 5-HD is thought to inhibit specifically the putative mitochondrial ATP-sensitive K+ (KATP) channel, this channel has been infer …
5-Hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for beta-oxidation of fatty acids.
Hanley PJ, Dröse S, Brandt U, Lareau RA, Banerjee AL, Srivastava DK, Banaszak LJ, Barycki JJ, Van Veldhoven PP, Daut J. Hanley PJ, et al. J Physiol. 2005 Jan 15;562(Pt 2):307-18. doi: 10.1113/jphysiol.2004.073932. Epub 2004 Oct 28. J Physiol. 2005. PMID: 15513944 Free PMC article.
5-Hydroxydecanoate (5-HD) blocks pharmacological and ischaemic preconditioning, and has been postulated to be a specific inhibitor of mitochondrial ATP-sensitive K(+) (K(ATP)) channels. However, recent work has shown that 5-HD is activated to 5-hydroxydecanoyl-CoA ( …
5-Hydroxydecanoate (5-HD) blocks pharmacological and ischaemic preconditioning, and has been postulated to be a specific inhibitor of mitoch …
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page